Overview

Bioavailability Study of 300 mg Trazodone Hydrochloride (New Polymer) vs. 300 mg Trazodone Hydrochloride (Contramid® Prolonged-release Tablets) Under Fasting Conditions

Status:
Completed

Trial end date:
2020-07-19

Target enrollment:

Participant gender:

Summary

This study was designed to investigate the bioequivalence of the test and reference products when administered as single oral doses in two consecutive study periods, under fasting conditions.

Phase:

Phase 1

Details

Lead Sponsor:

Aziende Chimiche Riunite Angelini Francesco S.p.A

Collaborator:

Cross Research S.A.

Treatments:

Trazodone